Interim Analysis of the 2nd Chance Protocol: A Multicenter Trial of Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for Relapsed/Refractory Myeloma with Salvage Autologous Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要